tiprankstipranks
Trending News
More News >
Siemens Healthineers AG Unsponsored ADR (SMMNY)
OTHER OTC:SMMNY
US Market

Siemens Healthineers AG Unsponsored ADR (SMMNY) Price & Analysis

Compare
3 Followers

SMMNY Stock Chart & Stats

$26.02
--
Market closed
$26.02
--

Siemens Healthineers AG Unsponsored ADR News

SMMNY FAQ

What was Siemens Healthineers AG Unsponsored ADR’s price range in the past 12 months?
Siemens Healthineers AG Unsponsored ADR lowest stock price was $23.42 and its highest was $30.26 in the past 12 months.
    What is Siemens Healthineers AG Unsponsored ADR’s market cap?
    Siemens Healthineers AG Unsponsored ADR’s market cap is $58.53B.
      When is Siemens Healthineers AG Unsponsored ADR’s upcoming earnings report date?
      Siemens Healthineers AG Unsponsored ADR’s upcoming earnings report date is Jan 29, 2026 which is in 33 days.
        How were Siemens Healthineers AG Unsponsored ADR’s earnings last quarter?
        Siemens Healthineers AG Unsponsored ADR released its earnings results on Nov 05, 2025. The company reported $0.39 earnings per share for the quarter, missing the consensus estimate of $0.399 by -$0.009.
          Is Siemens Healthineers AG Unsponsored ADR overvalued?
          According to Wall Street analysts Siemens Healthineers AG Unsponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Siemens Healthineers AG Unsponsored ADR pay dividends?
            Siemens Healthineers AG Unsponsored ADR pays a Annually dividend of $0.521 which represents an annual dividend yield of 1.98%. See more information on Siemens Healthineers AG Unsponsored ADR dividends here
              What is Siemens Healthineers AG Unsponsored ADR’s EPS estimate?
              Siemens Healthineers AG Unsponsored ADR’s EPS estimate is 0.27.
                How many shares outstanding does Siemens Healthineers AG Unsponsored ADR have?
                Siemens Healthineers AG Unsponsored ADR has 2,256,000,000 shares outstanding.
                  What happened to Siemens Healthineers AG Unsponsored ADR’s price movement after its last earnings report?
                  Siemens Healthineers AG Unsponsored ADR reported an EPS of $0.39 in its last earnings report, missing expectations of $0.399. Following the earnings report the stock price went down -8.728%.
                    Which hedge fund is a major shareholder of Siemens Healthineers AG Unsponsored ADR?
                    Currently, no hedge funds are holding shares in SMMNY
                    What is the TipRanks Smart Score and how is it calculated?
                    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                      Siemens Healthineers AG Unsponsored ADR Stock Smart Score

                      6
                      Neutral
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10

                      Company Description

                      Siemens Healthineers AG Unsponsored ADR

                      Siemens Healthineers AG Unsponsored ADR (SMMNY) is a global leader in medical technology and healthcare solutions, providing innovative and high-quality products and services in the fields of imaging, diagnostics, and digital health. The company operates primarily in the healthcare sector, focusing on areas such as imaging systems (including MRI, CT, and ultrasound), laboratory diagnostics, and advanced therapies. Siemens Healthineers aims to enhance patient care by delivering cutting-edge technologies and solutions that improve clinical outcomes and operational efficiency in healthcare settings.

                      Siemens Healthineers AG Unsponsored ADR (SMMNY) Earnings & Revenues

                      SMMNY Company Deck

                      SMMNY Earnings Call

                      Q4 2025
                      0:00 / 0:00
                      Earnings Call Sentiment|Neutral
                      The earnings call highlights Siemens Healthineers' strong performance in fiscal year '25, achieving the upper end of their guidance, with significant growth in Imaging, Varian, and Advanced Therapies. However, challenges in China, tariff impacts, and lower revenue guidance for Q1 2026 present notable concerns.View all SMMNY earnings summaries

                      SMMNY Stock 12 Month Forecast

                      Average Price Target

                      $28.00
                      ▲(7.61% Upside)
                      {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"23":"$23","26":"$26","29":"$29","24.5":"$24.5","27.5":"$27.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[23,24.5,26,27.5,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.77,25.018461538461537,25.266923076923078,25.515384615384615,25.763846153846153,26.012307692307694,26.26076923076923,26.50923076923077,26.757692307692306,27.006153846153847,27.254615384615384,27.50307692307692,27.751538461538463,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.77,25.018461538461537,25.266923076923078,25.515384615384615,25.763846153846153,26.012307692307694,26.26076923076923,26.50923076923077,26.757692307692306,27.006153846153847,27.254615384615384,27.50307692307692,27.751538461538463,{"y":28,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.77,25.018461538461537,25.266923076923078,25.515384615384615,25.763846153846153,26.012307692307694,26.26076923076923,26.50923076923077,26.757692307692306,27.006153846153847,27.254615384615384,27.50307692307692,27.751538461538463,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.85,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.24,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":28.28,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.96,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.09,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.73,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.18,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.63,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.82,"date":1754006400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.98,"date":1756684800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.19,"date":1759276800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.77,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Abbott Laboratories
                      Boston Scientific
                      Koninklijke Philips
                      Medtronic
                      Stryker

                      Ownership Overview

                      <0.01%99.99%
                      Insiders
                      <0.01% Other Institutional Investors
                      99.99% Public Companies and
                      Individual Investors

                      Options Prices

                      Currently, No data available
                      ---
                      Popular Stocks